P. Narayan et al., TRANSURETHRAL EVAPORATION OF THE PROSTATE FOR TREATMENT OF BENIGN PROSTATIC HYPERPLASIA - RESULTS IN 168 PATIENTS WITH UP TO 12 MONTHS OF FOLLOW-UP, The Journal of urology, 157(4), 1997, pp. 1309-1312
Purpose: We assessed the safety and efficacy of transurethral evaporat
ion of the prostate for the treatment of symptomatic benign prostatic
hyperplasia (BPH). Materials and Methods: A total of 168 patients with
symptomatic BPH underwent transurethral evaporation of the prostate.
Peak flow rate, American Urological Association symptom index and post
-void residual were assessed at baseline, and at 3, 6 and 12 months of
followup. Results: We found a statistically significant decrease in m
ean American Urological Association symptom index from 20.6 at baselin
e to 7.2 at 12 months (mean difference 13.4, 65% reduction, p <0.0001)
. We also found a statistically significant improvement in mean peak f
low rate from 8.2 to 18.2 cc per second, respectively (mean difference
10, 122% increase, p <0.0001). The most frequent complications were i
rritative voiding symptoms in 22.6% of patients and urinary tract infe
ctions in 4.8%. There were no additional major complications. Conclusi
ons: From these results transurethral evaporation of the prostate appe
ars to be safe and effective for treatment of BPH at 12 months of foll
owup.